<DOC>
	<DOC>NCT00690443</DOC>
	<brief_summary>Evaluate the efficacy of combination therapy AEGR-733 plus atorvastatin 20 mg versus monotherapy on serum lipoproteins over 4 and 8 weeks of therapy. The primary efficacy parameter is percent change in LDL-C after 8 weeks of therapy.</brief_summary>
	<brief_title>Evaluate Safety and Efficacy of AEGR-733 and Atorvastatin vs Atorvastatin Monotherapy in Hypercholesterolemia</brief_title>
	<detailed_description>Following a 35-day washout of current lipid-lowering medication (if any) and adherence to a low-fat diet, subjects will receive either atorvastatin 20 mg for 8 weeks, OR AEGR-733 2.5 mg + atorvastatin 20 mg for 4 weeks followed by AEGR-733 5 mg + atorvastatin 20 mg for 4 additional weeks. During the entire study, subjects will be instructed to follow a low-fat/low cholesterol diet and limit alcohol consumption to -/&lt; 1 drink per day.</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>M/F 1870 01 risk factor, mean LDLC /&gt; 160 and /&lt; 250 mg/dL (Visit 2 &amp; 3) 2+ risk factors, mean LDLC /&gt; 130 &amp; /&lt; 250 mg/dL (Visit 2 &amp; 3) Fasting mean TGs /&lt; 400 mg/dL Understanding and compliance of protocol sign consent Females pregnant, lactating, or CBP who have not been using acceptable contraceptive methods over previous 3 months Uncontrolled hypertension &gt;180/95 at screening Hx of chronic renal insufficiency (serum creatinine &gt; 2.5 mg/dL) Hx of liver disease or transaminases &gt; 1.5 X ULN Positive for Hepatitis B or C Major surgery within past 3 mos Cardiac insufficiency defined as functional Class IIClass IV Hx of malignancy within previous 5 years Participation in another investigational drug study within past 6 wks Serious or unstable medical or psychological condition Regular alcohol use &gt; 1 drink per day Regular consumers of grapefruit juice or medications known to be metabolized by CYP 3A4 Use of other lipidlowering meds (washout permitted) Acute CVD Diabetes Mellitus Fasting glucose &gt;110 mg/dL BMI /&gt; 40 kg/m2 Significant gastrointestinal symptoms such as IBS Use of fish oils, niacin, herbal wt. loss products (washout permitted)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Hyperlipidemia</keyword>
</DOC>